Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 4/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776322 | 0.88 | NPC1 (0.44) | GAASMN1; SMN2MEN1KMT2ACA2 | |
| SCHEMBL16776432 | 0.86 | CA2 (0.40) | EPHB4FAAHGAASMN1; SMN2MEN1 | |
| SCHEMBL16776315 | 0.85 | MCHR1 (0.41) | EPHB4SMN1; SMN2MEN1POLBKMT2A | |
| SCHEMBL16776329 | 0.84 | FYN (0.42) | FAAHGAASMN1; SMN2POLBCA2 | |
| SCHEMBL16776332 | 0.84 | CNR2 (0.51) | FAAHDCUN1D1MEN1KMT2A | |
| SCHEMBL16776367 | 0.83 | NPC1 (0.44) | MEN1KMT2ACA2CA9 | |
| SCHEMBL16776321 | 0.82 | FYN (0.44) | SMN1; SMN2MEN1KMT2ACA2CA9 | |
| SCHEMBL16776165 | 0.82 | CA2 (0.43) | FAAHGAASMN1; SMN2KMT2ACA2 | |
| SCHEMBL16776363 | 0.82 | CYP1A2 (0.49) | MEN1KMT2ACA2CA9 | |
| SCHEMBL16775824 | 0.82 | HTR2A (0.50) | FAAHMEN1KMT2ACA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | EPHB4 4864/4885ACP1 3472/4885FAAH 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.